logo-loader
viewHemoGenyx Pharmaceuticals

Hemogenyx files new patent application for CDX technology

The application covers the antibody's use in conditioning patients for bone marrow transplant and its deployment in a number of hard-to-treat blood borne diseases, including acute myeloid leukaemia

blood in vials
The drug under development should provide a "new, effective and safe method of conditioning patients for bone marrow transplants"

HemoGenyx Pharmaceuticals PLC (LON:HEMO) has filed a new patent application for its CDX antibody.

It covers its use in conditioning patients for bone marrow transplant and its deployment in a number of hard-to-treat blood borne diseases, including acute myeloid leukaemia (AML).

On the latter, the application covers the composition sequences of newly-discovered monoclonal antibodies against a target protein expressed on the surface of hematopoietic stem cells of certain types of leukaemia.

"Filing this patent is an important development and further solidifies Hemogenyx's leadership position in the development of new methods of bone marrow transplantation and treatments for blood cancers such as AML, acute lymphoblastic leukemia and possibly others,” said Hemogenyx chief executive, Dr Vladislav Sandler.

“The antibody we are developing, CDX, should, if successful, provide a new, effective and safe method of conditioning patients for bone marrow transplants, and has the potential to be a superior pharmaceutical for the treatment of blood cancers, for which survival rates are currently very poor."

Quick facts: HemoGenyx Pharmaceuticals

Price: 6.066 GBX

LSE:HEMO
Market: LSE
Market Cap: £26.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

2 min read